Graphical Abstract Highlights d IL-17 mediates paclitaxel-induced neuropathic pain by T-cell-independent mechanism d IL-17 regulates pain via neuron-glial interactions both in the spinal cord and DRG d Overexpression of IL-17 in spinal astrocytes induces mechanical allodynia d Blockade of IL-17R suppresses neuronal hyperexcitability induced by paclitaxel
Correspondence
In Brief Luo et al. find that glia-produced IL-17 regulates synaptic transmission and excitability of spinal SOM + neurons and DRG small neurons by IL-17R in the DRG and spinal pain circuit. These results suggest that IL-17/IL-17R mediate neuron-glial interactions and drives chemotherapy-induced neuropathic pain.
The proinflammatory cytokine interleukin-17 (IL-17) is implicated in pain regulation. However, the synaptic mechanisms by which IL-17 regulates pain transmission are unknown. Here, we report that glia-produced IL-17 suppresses inhibitory synaptic transmission in the spinal cord pain circuit and drives chemotherapy-induced neuropathic pain. We find that IL-17 not only enhances excitatory postsynaptic currents (EPSCs) but also suppresses inhibitory postsynaptic synaptic currents (IPSCs) and GABAinduced currents in lamina II o somatostatin-expressing neurons in mouse spinal cord slices. IL-17 mainly expresses in spinal cord astrocytes, and its receptor IL-17R is detected in somatostatin-expressing neurons. Selective knockdown of IL-17R in spinal somatostatin-expressing interneurons reduces paclitaxel-induced hypersensitivity. Overexpression of IL-17 in spinal astrocytes is sufficient to induce mechanical allodynia in naive animals. In dorsal root ganglia, IL-17R expression in nociceptive sensory neurons is sufficient and required for inducing neuronal hyperexcitability after paclitaxel. Together, our data show that IL-17/IL-17R mediate neuron-glial interactions and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy.
INTRODUCTION
Proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-a), interleukin-1b (IL-1b), and IL-18 play important roles in the pathogenesis of chronic pain (Yang et al., 2015; Sweitzer et al., 1999; Guo et al., 2007; Sommer, 1999; Zelenka et al., 2005; Milligan et al., 2001; Miyoshi et al., 2008) . Increasing evidence suggests that glial cells, such as microglia and astrocytes, are activated in pathological pain conditions to produce these proinflammatory cytokines. Notably, these cytokines act as neuromodulators and regulate pain via neuron-glial interactions Grace et al., 2014) . Compared to the inflammatory cytokines TNF, IL-1b, and IL-6, much less is known about the role of IL-17 in pain regulation. IL-17, referred to as IL-17A in literature, is a proinflammatory cytokine produced by Th17 cells (Miossec and Kolls, 2012; Korn et al., 2009 ). The IL-17 family consists of six ligands (IL-17A-IL-17F) and five receptors (IL-17RA-IL-17RE) in mammals (Gaffen, 2009 ). IL-17 was shown to regulate rheumatoid arthritis and immune response by increasing the production of IL-6 and IL-8 (Hwang et al., 2004) . Binding of IL-17 to its receptor (IL-17RA or IL-17R) induces the activation of nuclear factor-kB (NF-kB) via ACT1 and TNF-receptor-associated factor 6 (TRAF6) in rheumatoid arthritis (Hot and Miossec, 2011) . However, little is known about non-transcriptional regulation of IL-17.
Recently, IL-17 was found to regulate inflammatory responses associated with neuropathic pain induced by nerve injury. IL-17 levels are upregulated in injured nerves in neuropathic pain models (Noma et al., 2011; Kleinschnitz et al., 2006) . IL-17 receptor (IL-17R) was detected in most neurons in dorsal root ganglion (DRG) sections as well as in cultured DRG neurons (Segond von Banchet et al., 2013; Richter et al., 2012) . IL-17A-deficient mice showed decreased mechanical hyperalgesia compared to normal mice in response to zymosan injection (Segond von Banchet et al., 2013) or partial ligation of the sciatic nerve (Kim and Moalem-Taylor, 2011) . Furthermore, intraplantar (Kim and Moalem-Taylor, 2011; McNamee et al., 2011) or intra-articular (Pinto et al., 2010) injection of recombinant IL-17 is sufficient to induce hyperalgesia. Notably, IL-17 can also be produced by spinal cord astrocytes and astrocytic IL-17 may play a role in inflammatory pain (Meng et al., 2013) . A recent study found that physiological levels of IL-17 can act directly on interneurons to increase their responsiveness to presynaptic input (Chen et al., 2017a) . Despite these previous studies, it remains elusive how IL-17 modulates spinal synaptic transmission in the pain circuit.
Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting adverse side effect and results in high incidence of neuropathic pain (Sisignano et al., 2014) . There is evidence that spinal astrocytes, but not microglia, play an important role in the pathogenesis of paclitaxel-induced neuropathy (Zhang et al., 2012; Luo et al., 2018) . CIPN enhances excitability of primary sensory neurons associated with altered gene expression of neuronal ion channels (Zhang and Dougherty, 2014) and also increases excitatory synaptic transmission in spinal cord substantia gelatinosa neurons . It remains elusive as to how cytokines, such as IL-17, regulate synaptic plasticity in CIPN.
Somatostatin-positive (SOM + ) neurons are a subset of interneurons in the dorsal horn. These neurons are predominantly excitatory and express the vesicular glutamate transporter VGLUT 2 , a marker for glutamatergic excitatory neurons (Duan et al., 2018; Xie et al., 2018) . Recently, Duan et al. (2014) demonstrated that SOM + neurons are required to sense mechanical pain. These neurons form a pain circuit by receiving input from capsaicin-sensitive C-fibers and sending output to lamina I projection neurons (Todd, 2010; Braz et al., 2014) . SOM + neurons also receive input from inhibitory neurons (Duan et al., 2014) . Furthermore, these neurons exhibit remarkable plastic changes after inflammation and nerve injury as well as respond to inflammatory mediators (Park et al., 2011; Xie et al., 2018; Xu et al., 2010) . Here, we investigated how IL-17 and IL-17R modulate excitatory and inhibitory synaptic transmission of SOM + excitatory neurons in normal and pathological pain conditions, and we further tested the involvement of IL-17/IL-17R signaling in the paclitaxel-induced neuropathic pain model. Our findings demonstrate that IL-17 signaling contributes to paclitaxel-induced mechanical allodynia and the dysregulation of excitatory and inhibitory synaptic transmission in spinal SOM + neurons. Moreover, we reveal an insight into neuron-glial interactions in the spinal cord and DRG by which IL-17 produced by astroglia or satellite glia enhance neuronal activities and excitability to promote neuropathic pain.
RESULTS

IL-17 Enhances Excitatory Synaptic Transmission and Potentiates NMDA-Mediated eEPSCs in Spinal Cord
Slices SOM + neurons in the spinal dorsal horn are excitatory interneurons (Duan et al., 2014 (Duan et al., , 2018 . These neurons exhibit marked synaptic plasticity in pathological pain conditions (Xie et al., 2018; Xu et al., 2013) . We first recorded spontaneous excitatory postsynaptic currents (sEPSCs) in outer lamina II (II o ) SOM + neurons in spi-nal cord slices from SOM-tdTomato mice ( Figure 1A ). Acute perfusion of IL-17 at a low concentration (10 ng/mL; z6.7 3 10 À1 nM; 2-5 min) induced a rapid and significant increase in the frequency but did not amplitude of sEPSCs in 19 out of 22 neurons ( Figures  1B-1F ), suggesting a possible presynaptic mechanism of IL-17 to enhance glutamate release ( Figure S6 ). Notably, IL-17 produced a 66% increase in sEPSC frequency (paired t test; t 0.01,18 = 9.34; p < 0.0001). Because excitatory synaptic transmission is mainly mediated by AMPA and NMDA receptors (AMPAR and NMDAR) and NMDAR in particular is critical for spinal cord synaptic plasticity and the pathogenesis of pain (Woolf and Salter, 2000; Liu et al., 2008) , we further examined the effects of IL-17 on NMDAR-EPSCs evoked by dorsal root entry zone (Lissauer's tract) stimulation. The amplitude of NMDAR-EPSC was also significantly increased by  37%; paired t test; t 0.01,5 = 4.296; p = 0.0077), suggesting the positive regulation of excitatory synaptic transmission by IL-17.
IL-17 Decreases the Inhibitory Control of SOM + Neurons and Suppresses GABA-Induced Currents SOM + excitatory neurons receive inhibitory input from inhibitory neurons (Duan et al., 2014) . We next recorded spontaneous inhibitory postsynaptic synaptic currents (sIPSCs) in lamina II o SOM + neurons by using a pipette solution containing Cs + . After exposure of spinal cord slices to IL-17 (10 ng/mL) for 2-5 min, most of the recorded neurons (7 out of 10) responded to IL-17. IL-17 produced significant decreases in sIPSC frequency  paired t test; t 0.01,6 = 4.541; p = 0.0039) and amplitude ( Figures 1I, 1L , and 1M; paired t test; t 0.01,7 = 4.833; p = 0.0019). Because inhibitory synaptic transmission in the spinal cord is mediated by GABA and glycine, two major inhibitory neurotransmitters (Todd, 2010) , we further assessed whether IL-17 would also alter GABA-and glycine-evoked currents in lamina II o SOM + neurons. Bath application of GABA (100 mM) and glycine (1 mM) induced marked inward currents. Neither GABA nor glycine current was affected by vehicle perfusion ( Figures  1N-1Q ). Interestingly, acute application of IL-17 (10 ng/mL) only inhibited GABA-induced currents ( Figures 1N and 1O ; Student's t test; t 0.01,10 = 2.456; p = 0.0339) but had no effect on glycine-induced currents in spinal SOM + neurons ( Figures  1P and 1Q ; Student's t test; t 0.01,8 = 0.1032; p = 0.9204), suggesting specific regulation by IL-17 on GABAR-mediated inhibitory synaptic transmission ( Figure S6 ).
Upregulation of Endogenous IL-17 and IL-17R Regulates Synaptic Plasticity and Excitability of SOM + Neurons in
Paclitaxel-Treated Mice CIPN results in high incidence of neuropathic pain (Sisignano et al., 2014) . A single injection of paclitaxel (6 mg/kg, intraperitoneally [i.p.]) can evoke a remarkable mechanical allodynia on day Student's t test; CSF: t 0.05,10 = 2.706, p = 0.022; spinal dorsal horn: t 0.01,9 = 3.305, p = 0.009). To examine whether upregulated IL-17 by chemotherapy contributes to spinal cord synaptic plasticity (i.e., central sensitization), a driving force of pathological pain (Woolf and Salter, 2000; Ji et al., 2018) , we measured the frequency and amplitude of sEPSCs or sIPSCs of spinal SOM + neurons in paclitaxel-treated mice. Blocking IL-17R with a neutralizing antibody (0.5 mg/mL z4.17 nM) resulted in opposite changes in excitatory and inhibitory synaptic transmission in lamina II o SOM + neurons of paclitaxel-treated animals, namely a decrease in the frequency of sEPSCs ( Figures 2C-2E ; Student's t test; t 0.05,12 = 2.516; p = 0.027) but increases in sIPSC frequency (Figures 2F and 2G; Student's t test; t 0.05,14 = 2.552; p = 0.0213) and sIPSC amplitude (Figures 2F and 2H; Student's t test; t 0.05,14 = 2.226; p = 0.043), suggesting the involvement of endogenous IL-17 in synaptic plasticity after CIPN. Immunohistochemistry in SOM-reporter mice revealed IL-17R immunoreactivity (IR) and IL-17R mRNA expressed on SOM-positive neurons in the spinal dorsal horn ( Figures 2I, 2J , and S1A). Additionally, about half of IL-17R expressed on PAX2 (an inhibitory neuronal marker)-positive neurons (Figures 2J and 2K) . These data provided a cellular basis for IL-17 directly or indirectly by inhibitory interneurons to regulate the activities of SOM + neurons ( Figure S6 ).
To further determine the effects of IL-17R in SOM-positive neurons of spinal dorsal horn, Cre-recombinase-dependent adeno-associated virus (AAV) expressing IL-17R-short hairpin RNA (shRNA) (AAV2/ 9-DIO-EGFP-IL-17R-shRNA) was intradorsal horn injected in SOM-Cre mice to selectively knock down IL-17R in spinal SOM + neurons ( Figure S1B ). Consistent with IL-17R antibody, selective knockdown of IL-17R in spinal SOM + neurons significantly suppressed the frequency of sEPSCs, but not sEPSCs amplitude of SOM + neurons, in paclitaxel-treated mice (Figures 3A-3E; Student's t test; t 0.05,27 = 4.309; p = 0.0002).
We subsequently determined whether paclitaxel-induced CIPN would alter the excitability of spinal SOM + neurons. Action potentials (APs) were evoked by superimposed positive current steps. A leftward shift in the input-output curve appeared in paclitaxel-treated mice, and significantly, differences were observed after current injections ranging from 15 to 65 pA ( Figures 3F and 3G ; two-way ANOVA; treatment: F 1,168 = 94.2; p < 0.0001). Additionally, a more positive resting membrane potential and a lower rheobase were observed in SOM + neurons taken from paclitaxel-treated mice as compared with that from controls ( Figures 3H and 3I ). For selective knockdown of IL-17R in SOM-expressing neurons, we expressed IL-17R-targeting shRNA in the spinal cord via intra-spinal cord microinjection. Treatment of AAV2/9-DIO-EGFP-IL-17R-shRNA in SOM-Cre mice prevented paclitaxel-induced hyperexcitability in SOM + neurons ( Figures 3F and 3H-3J ). Collectively, these results suggest that endogenous IL-17 is involved in modulating excitatory and inhibitory synaptic transmission and regulating excitability in spinal SOM + neurons via IL-17R after paclitaxel treatment, suggesting a role of the IL-17/IL-17R pathway in CIPN.
Cellular Localization of IL-17 and IL-17R in the Spinal Dorsal Horn
Spinal astrocytes play an important role in the pathogenesis of paclitaxel-induced neuropathy (Zhang et al., 2012; Luo et al., 2018) . Paclitaxel-induced IL-17 upregulation in spinal CSF and spinal cord dorsal horn tissues suggests a possible spinal source of IL-17. To determine an astrocytic location of IL-17, we conducted double immunofluorescence of IL-17 with two astrocyte markers, GFAP and ALDH1L1 in spinal cord sections. The result showed that IL-17-IR was primarily colocalized with the GFAP and ALDH1L1, but not with the neuronal marker NeuN and the microglia marker IBA1 in spinal dorsal horn ( Figures 4A-4D) . Notably, IL-17-IR was found in fine and end processes of astrocytes ( Figure 4B ), indicating a possibility of IL-17 transport from cell body to end processes for secretion. The selectivity of IL-17-IR was validated by colocalization with td-Tomato signal in astrocytic processes in IL-17-reported mice ( Figure S2 ). To further examine whether these IL-17-labeled dot-like structures are nerve terminals of nociceptors, we performed double staining of IL-17 with CGRP, a marker for peptidergic nociceptors, and IB4, a marker for non-peptidergic nociceptors. Notably, no colocalized immunoreactivities of IL-17 with IB4 + and CGRP + primary afferent terminals were detected ( Figure S3 ). Thus, IL-17 may not be present on nociceptor terminals in the spinal cord dorsal horn. Fluorescence in situ hybridization (FISH) further demonstrated the colocalization of IL-17 mRNA and GFAP (Figures 4E and 4F) . Interestingly, IL-17 mRNA puncta were found in processes of astrocytes, suggesting a local translation ( Figures  4E and 4F) . Differently, IL-17R was primarily expressed on spinal cord neurons ( Figure 4G ), including SOM + and PAX2 + neurons ( Figures 3I-3K ). Some IL-17R immunoreactivities colocalized with GFAP-positive astrocytes but did not with IBA1-postive microglia ( Figures 4H and 4I ). This localization of IL-17 and IL-17R in spinal astrocytes and neurons, respectively, offers a cellular basis for neuron-astroglial interaction during pain regulation.
IL-17 Increases the Excitability of Small-Sized Mouse DRG Neurons
Next, we examined whether IL-17 and IL-17R also display distinct cellular locations in DRG. Immunostaining revealed that IL-17R expressed in small-sized mouse DRG IB4 + and CGRP + with a predominant in IB4 + neurons but did not in large-sized NF-200 + neurons ( Figure 5A ). This is consistent with a previous report that IL-17RA is localized to rat DRG neu-rons (Richter et al., 2012) . In contrast, IL-17 mainly expressed in DRG satellite glial cells expressing glutamine synthetase (GS), in IL-17 reporter mice expressing Td-Tomato, or GFP (Figures S4A and S4B) . Thus, IL-17 and IL-17R in peripheral nervous systems may also mediate glial-neuron interactions ( Figure S7 ).
To determine a role of IL-17 in regulating the excitability of DRG neurons, we tested the effects of IL-17 on neuronal activities in dissociated small-sized mouse DRG neurons (<25 mm in diameter) using whole-cell patch-clamp recordings. Acute application of IL-17 (10 ng/mL) to mouse DRG neurons in vitro induced spontaneous discharge and bursts of APs in some DRG neurons (Figure 5B) . Also, IL-17 significantly depolarized the resting membrane potential ( Figure 5C ; paired t test; t 0.01,10 = 4.219; p = 0.0018) and significantly decreased rheobase ( Figure 5D ; paired t test; t 0.01,10 = 4.033; p = 0.0024). Additionally, IL-17 bath application increased the number of AP discharges in response to suprathreshold current injection ( Figures 5E and 5F ; two-way repeated measures [RMs] ANOVA; treatment: F 1,120 = 138.9; p < 0.0001). Therefore, IL-17 increases the excitability of nociceptive neurons by altering rheobase and resting membrane potential in nociceptive neurons, leading to enhanced discharges of APs.
IL-17R Is Required for Generating Hyperexcitability of Mouse DRG Neurons after Paclitaxel Chemotherapy
Paclitaxel has been shown to increase the responsiveness and excitability of mouse and human DRG neurons (Chang et al., 2018; Li et al., 2015) . We compared the number of APs evoked by a 600-ms current injection through an intracellular electrode in mouse DRG neurons by testing the effects of paclitaxel after bath application (1 mM; 2 h). Only neurons that showed more than one AP in response to stimulation were included in the analysis. Paclitaxel increased the AP firing number in small-sized neurons compared with the vehicle-treated neurons ( Figures 6A and  6B ; two-way RM ANOVA; treatment: F 1,144 = 80.89; p < 0.0001). Strikingly, this excitability increase was suppressed by IL-17RA antibody treatment when compared to control immunoglobulin G (IgG) treatment ( Figures 6C and 6D ; two-way RM ANOVA; treatment: F 1,144 = 114; p < 0.0001). We also measured the number of AP discharges in response to suprathreshold current injection in paclitaxel-induced CIPN mice. The number of AP firings in small-sized DRG neurons from paclitaxel-treated mice was greater than that from control mice ( Figures 6E and 6F ; two-way RM ANOVA; treatment: F 1,130 = 72.5; p < 0.0001). To further confirm the effect of IL-17R in DRG neurons on paclitaxel-induced hyperexcitability, AAV2/9-SYN-EGFP-IL-17Ra-shRNA was intra-DRG injected to selectively knock down IL-17RA on DRG neurons in paclitaxel-treated CIPN mice ( Figure 6G ). As shown in Figures  6H and 6I , knockdown of IL-17RA in DRG neurons markedly attenuated the frequency of AP firings evoked by a 500-ms current injection (two-way RM ANOVA; treatment: F 1,195 = 92.14; p < 0.0001). This result implies direct regulation of neuronal hyperexcitability by IL-17R after chemotherapy ( Figure S7 ).
IL-17 and IL-17R Contribute to Mechanical Hypersensitivity after Chemotherapy
To test a central role of IL-17 in pain modulation, we compared mechanical pain thresholds of mice following intrathecal injection of IL-17 versus vehicle. Spinal injection of a low dose of intrathecally [i.t.] ) resulted in a transient reduction of paw withdrawal threshold (PWT) at 1 h after injection ( Figure 7A) . A higher dose of IL-17 (100 ng, i.t.) caused a more persistent reduction in PWT measured at 5 h following injection, with return of mechanical allodynia after 24 h ( Figure 7A ; two-way RM ANOVA; treatment: F 2,165 = 16.59; p < 0.0001). To address whether astrocyte-derived IL-17 mediates the mechanical allodynia, AAV2/9 expressing IL-17 driven by GFAP was intra-dorsal horn injected to overexpress IL-17 ( Figures 7B-7D) . These data suggest that IL-17 from astrocytes is sufficient to induce pain hypersensitivity in naive animals. The contribution of endogenous IL-17 to chemotherapy-evoked neuropathic pain was also examined. A single injection of paclitaxel (6 mg/kg, i.p.) evoked a remarkable reduction in PWT measurement on day 7, which was reversed by IL-17R antibody treatment (1 and 10 mg, i.t.) in a dose-dependent manner ( Figure 7E ; two-way RM ANOVA; treatment: F 2,115 = 3.598; p = 0.03). Intrathecal injection of control IgG (10 mg) produced no changes in PWT. To determine spinal SOM + neuron expressing IL-17R-mediated effect in paclitaxel-induced CIPN, AAV2/9-DIO-EGFP-IL-17R-shRNA was intra-dorsal horn injected in SOM-Cre mice to selectively knock down IL-17R in spinal dorsal horn SOM + neurons. Knockdown of Figure 6G ; two-way RM ANOVA; treatment: F 1,36 = 19.93; p < 0.0001). These results indicate that endogenous IL-17 and spinal as well as DRG IL-17R are required for the maintenance of chemotherapy-induced neuropathic pain.
T cell infiltration into the spinal cord may contribute to nerveinjury-induced mechanical allodynia (Sorge et al., 2015) . We therefore measured mechanical response threshold in a T-celldeficient mouse strain, Rag1 knockout mice, characterized by an absence of functional T cells (Nancy et al., 2012) . Intrathecal injection of IL-17R antibody (10 mg) or IL-17 antibody (2 mg) significantly relieved paclitaxel-induced mechanical allodynia ( Figure 7H ; two-way RM ANOVA; treatment: F 2,96 = 12.42; p < 0.0001), suggesting that (1) T cells may not be required for IL-17 signaling in CIPN and (2) glia-derived IL-17 plays a predominant role in paclitaxel-induced neuropathic pain. As a support, we did not observe colocalization of IL-17 and CD3 + T lymphocytes in the spinal dorsal horn ( Figure S5 ).
DISCUSSION
We have provided an insight into how IL-17 promotes chemotherapy-induced neuropathic pain. Our results show that IL-17 and IL-17R regulate neuropathic pain via multiple mechanisms, including neuron-glial interactions, central sensitization, and peripheral sensitization ( Figures S6 and S7 ). In the spinal cord, IL-17 enhances NMDA-receptormediated currents, facilitates excitatory synaptic transmission, and increases excitability of dorsal horn SOM + neurons. In particular, IL-17 suppresses inhibitory synaptic transmission by inhibiting GABA-receptor-mediated currents ( Figure S6 ). In the DRG, IL-17 increases neuronal excitability and IL-17R contributes to paclitaxel-induced nociceptor hyperactivity ( Figure S7 ).
IL-17 and IL-17R Mediate Neuron-Glial Interactions Both in the Central and Peripheral Nervous System
Recent progress has demonstrated the critical role of spinal glial cells in driving chronic pain via production of proinflammatory cytokines and neuron-glial interactions (Ji et al., 2016; McMahon and Malcangio, 2009; Ren and Dubner, 2010; Gosselin et al., 2010; Salter and Stevens, 2017; Tsuda, 2018) . Microglia and astrocytes play different roles in CIPN. Paclitaxel was shown to induce astrocyte activation, but not microglia activation, in the spinal cord (Zhang et al., 2012) . Activation of p38 mitogen-activated protein (MAP) kinase in spinal microglia contributes to neuropathic pain after nerve trauma and cancer pain (Jin et al., 2003; Yang et al., 2015) . However, spinal inhibition of p38 MAP kinase fails to affect chemotherapy-induced mechanical allodynia . Our results also highlight a role of astrocytes in CIPN. IL-17 is a T-cell-derived cytokine, but we did not see IL-17 expression in T cells ( Figure S5 ). In Rag1 knockout mice with T cell deficiency, paclitaxelinduced CIPN was developed as usual. Furthermore, inhibition of spinal IL-17 signaling was capable of suppressing CIPN in the immune-deficient mice, suggesting that IL-17 signaling in CIPN in both male and female mice may not require T cells. Intriguingly, we found IL-17 immunoreactivity exclusively in GFAP-expressing astrocytes. In contrast, IL-17R was primarily expressed in spinal cord neurons, including SOM + excitatory interneurons and PAX2 + inhibitory interneurons. This localization of IL-17 and IL-17R offers a cellular basis for neuron-astroglial interaction during pain regulation. We also observed respective expression of IL-17 and IL-17R in satellite glial cells and neurons in mouse DRG. Thus, IL-17/IL-17R signaling could promote both central sensitization and peripheral sensitization via neuron-glial interactions in the CNS and peripheral nervous system (PNS).
IL-17 and IL-17R Modulate Excitatory Synaptic Transmission in the Spinal Cord Pain Circuit
Enhanced excitatory synaptic transmission has been shown in spinal cord neurons, including SOM + neurons, in various pathological pain conditions (Yang et al., 2015; Chen et al., 2015) . Our data indicate that IL-17 is both sufficient and required for inducing this synaptic plasticity. Exogenous IL-17 rapidly increased EPSCs in spinal cord slices from naive animals. Spinal cord slices from paclitaxel-treated animals exhibited an increase in sEPSCs, which was suppressed by IL-17R antibody and IL-17R-shRNA, suggesting an endogenous role of IL-17 in CIPN. Mechanistically, IL-17 acutely enhanced the amplitude of NMDA-evoked currents following dorsal root stimulation, suggesting that IL-17 increases NMDAR activity via rapid posttranslational regulation. This is consistent with the previous report that IL-17 acts on spinal nociceptive neurons co-expressing IL-17R and NR1 to modulate pain (Meng et al., 2013) . NMDAR plays a critical role in the induction and maintenance of central sensitization during persistent pain conditions (Woolf and Thompson, 1991; South et al., 2003; Liu et al., 2008) . It remains to be investigated how IL-17 modulates NMDAR activity. It is possible that IL-17 activates protein kinases, such as extracellular-regulated kinase (ERK) and protein kinase C (PKC), to enhance NMDAR activation and neuronal excitability (Hu and Gereau, 2003) . For example, TNF-a increases NMDA currents in spinal cord lamina II o neurons via ERK phosphorylation (Xu et al., 2010) . In addition, Ca 2+ /calmodulin-dependent protein kinase II (Ca 2+ /CaM-KII) is involved in Ca 2+ signaling and hyperalgesia. CaM-KII inhibitors decreased many types of hyperalgesia, including neuropathic pain (Katano et al., 2011) . CaM-KII inhibitor KN-93 suppressed the neuropathic pain and NMDA GluN2B upregulation (Liu et al., 2018) . Yao et al. (2016) reported that IL-17 significantly increased phosph-CaMKII (p-CaMKII) levels in the spinal cord. L4 spinal nerve ligation (SNL)-induced p-CaMKII can be blocked by IL-17 antibody or IL-17 genetic deficiency. CaMKII inhibitor markedly relieved SNL-induced hyperalgesia and pCREB. CREB is essential for the regulation of pro-nociceptive genes and longterm neuronal plasticity . In neuropathic pain model, an increased phosphorylation of CREB can be induced, which is associated with spinal central sensitization (Miletic et al., 2002) . Spinal rIL-17 significantly increased pCREB levels, (E) Mechanical allodynia, induced by paclitaxel (6 mg/kg, i.p.) is attenuated by intrathecal injection of IL-17R antibody (1 and 10 mg). **p < 0.01 versus control IgG (10 mg, i.t.); two-way ANOVA; n = 7-11; mice. (F) Specific knockdown of IL-17R in spinal dorsal horn SOM + neurons by intra-dorsal horn injection of AAV2/9-DIO-EGFP-IL-17R-shRNA blocked paclitaxelinduced mechanical allodynia. **p < 0.01 versus control shRNA; # p < 0.05; ## p < 0.01 versus baseline (before i.p. PAX); two-way ANOVA; n = 6 and 8; mice. (G) Knockdown of IL-17R in DRG neurons by intra-DRG injection of AAV2/9-hSYN-EGFP-IL-17R-shRNA prevented and delayed paclitaxel-induced mechanical allodynia. *p < 0.05; **p < 0.01 versus control shRNA; # p < 0.05 versus baseline (before i.p. PAX); two-way ANOVA; n = 4 and 5; mice. (H) Mechanical allodynia is attenuated by intrathecal injection of IL-17R antibody (10 mg) or IL-17 antibody (2 mg) in Rag1 KO mice. *p < 0.05; ***p < 0.001 versus control IgG (10 mg, i.t.); two-way ANOVA; n = 5-6; mice. All data were mean ± SEM. See also Figure S5 . and blockage of IL-17 signaling decreased pCREB (Yao et al., 2016) . Thus, IL-17 may play a role in spinal pain modulation via ERK, CaM-KII, and PKC signaling pathways regulating spinal synaptic transmission.
Modulation of Inhibitory Synaptic Transmission by IL-17 and IL-17R
One of the most interesting findings of this study is the profound suppression of inhibitory synaptic transmission in lamina II o SOM + neurons. Disinhibition, i.e., loss of inhibitory synaptic transmission, is emerging as a key mechanism of neuropathic pain (Coull et al., 2003; Zeilhofer et al., 2012a; Lu et al., 2013; Coull et al., 2005) . Removal of spinal inhibition, especially presynaptic GABAergic inhibition, not only reduces the fidelity of normal sensory processing but also provokes symptoms very much reminiscent of inflammatory and neuropathic pain syndromes (Zeilhofer et al., 2012b; Takazawa et al., 2017; Chen et al., 2014) . Increasing evidence suggests that disinhibition is a key mechanism by which glial mediators (e.g., IL-1 and brain-derived neurotrophic factor [BDNF]) regulate central sensitization and chronic pain (Chen et al., 2018; Coull et al., 2005) . Our study shows that exogenous IL-17 rapidly (within 1 min) and drastically decreased the frequency and amplitude of sIPSCs. Mechanistically, IL-17 specifically suppressed GABAinduced currents, but not glycine-induced currents. Although TNF-a and IL-1b have also been shown to regulate inhibitory synaptic transmission in spinal cord neurons (Kawasaki et al., 2008; Zhang et al., 2010; Chirila et al., 2014) , they act on different pain circuits in the spinal cord. Multiple mechanisms have been implicated in disinhibition in pathological pain (Zeilhofer et al., 2012b) . Microglia-produced BDNF was shown to suppress GABA currents in lamina I projection neurons (Coull et al., 2005) . Our data suggest that IL-17 can elicit a very rapid loss of inhibition to open the spinal gate, which enables low-threshold mechanical stimuli to activate pain transmission neurons as predicted by the ''gate control theory'' (Melzack and Wall, 1965; Wall, 1978) . The majority of SOM + excitatory neurons are distributed in lamina II of the spinal cord. These neurons not only receive excitatory input from C-fibers, Ab-fibers, and Ad-fibers but also receive inhibitory control from inhibitory neurons (Duan et al., 2014) . Our present study showed that IL-17R was expressed in both SOM + excitatory and PAX2 + inhibitory interneurons in spinal cord. Thus, IL-17 may induce mechanical allodynia in chronic pain via distinct synaptic mechanisms either by increasing excitatory synaptic transmission or by decreasing inhibition control of SOM + excitatory neurons. Our working hypothesis is illustrated in Figure S6 . Interestingly, despite IL-17R expression in both SOM + and SOM À neurons, selective knockdown of IL-17R in spinal SOM + neurons almost completely reversed paclitaxel-induced alteration in excitability of spinal SOM + neurons ( Figures 3H-3J ). The possible explanations include that IL-17R-expressing SOM + neurons may play a predominant role; alternately, the local neural network of excitation and disinhibition of SOM + neurons may be critical for regulating neuronal excitability of SOM + neurons. Even so, the effect of IL-17R-expressing PAX2 + neurons can still be detected. For example, following selective knockdown of IL-17R in spinal SOM + neurons, paclitaxel-treated mice can also develop me-chanical allodynia at 10 days ( Figure 7F ), suggesting IL-17R-expressing SOM À neurons contribute to paclitaxel-induced neuropathic pain in a late phase.
Modulation of DRG Neuronal Excitability after Chemotherapy
Paclitaxel (Taxol) is a widely used chemotherapeutic agent producing a neuropathy characterized by pronounced impairment of function in A-beta myelinated fibers, intermediate impairment of A-delta myelinated fibers, a relative sparing of C-fibers (Dougherty et al., 2004) , and mechanical hypersensitivity (hyperalgesia and allodynia; Polomano et al., 2001; Fossiez et al., 1996) . Mechanical allodynia after paclitaxel treatment is mediated by both C-fibers and A-beta fibers (Xu et al., 2015) . Paclitaxel increases excitability of DRG neurons via regulating the expression and function of ion channels, such as TRPV1, TRPV4, HCN1, and Nav1.7, leading to increased excitatory synaptic input to spinal cord substantia gelatinosa (SG) neurons (Chang et al., 2018; Li et al., 2015; Zhang and Dougherty, 2014) . Peripheral mechanisms of pain modulation by IL-17 have been investigated. For example, IL-17 sensitizes joint nociceptors to mechanical stimuli to facilitate arthritic pain (Richter et al., 2012) . It was also reported that neuronal IL-17R regulates mechanical, but not thermal, hyperalgesia by upregulation of TRPV4, but not TRPV1, in DRG neurons (Segond von Banchet et al., 2013) . We observed rapid excitability increase in both mouse and human DRG neurons following IL-17 treatment, suggesting possible post-translational modulations to some key ion channels, such as sodium channels. Our work in progress shows that IL-17 also increased sodium currents (data not shown). Interestingly, we found that the enhanced excitability in paclitaxel-pretreated small mouse DRG neurons can be abolished by a neutralizing antibody against IL-17R antibody and IL-17R-shRNA. Because the recordings were conducted in dissociated neurons and the physiological concentration of IL-17 is not present in culture medium, our result suggests a possibility that IL-17R may directly regulate neuronal activity in the absence of IL-17. Future studies will examine how IL-17R interacts with ion channels, such as Nav1.7. We should not rule out the possibility that satellite glial cells may also be attached to neurons in our culture conditions and communicate with neurons by releasing IL-17. Our working hypothesis of peripheral glial regulation of chemotherapy-evoked neuropathic pain via IL-17/IL-17R signaling is illustrated in Figure S7 .
Translational Potential IL-17 levels in the sciatic nerve are elevated after nerve injury (Noma et al., 2011) . Our data show that IL-17 levels are also elevated in the CSF and spinal cord in paclitaxel-treated mice. Importantly, intrathecal injection of IL-17R antibody or selective knockdown of IL-17R in DRG neurons or spinal SOM + neurons effectively alleviated paclitaxel-induced neuropathic pain. Chemotherapy has been shown to activate cancer-associated fibroblasts, which leads to renewal of cancer-initiating cells and maintenance of colorectal cancer by IL-17 secretion (Lotti et al., 2013) . Thus, targeting IL-17 signaling may not only alleviate neuropathic pain but also improve anti-cancer efficacy after chemotherapy. The translational potential of this study is enhanced by demonstrating hyperexcitability of human sensory neurons in response to IL-17. IL-17 blockers have been developed for treating inflammatory diseases, such as psoriasis and arthritis (Kivelevitch and Menter, 2015) . Brodalumab (Kyntheum) is a human anti-interleukin-17 receptor A (IL-17RA) monoclonal antibody available for use in patients with moderate to severe plaque psoriasis (Blair, 2018) . Because mouse IL-17RA antibody is effective in suppressing neuronal hyperexcitability after paclitaxel, brodalumab could be used to treat CIPN and neuropathic pain.
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